You will be able to find all of our recent and archived news announcements. Our press releases are intended for business journalists and analysts/investors.
ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment
ViiV Healthcare today announced the start of a phase III programme to support regulatory filings for a two-drug regimen of dolutegravir (Tivicay®) and lamivudine (Epivir®) as a treatment for HIV-1 infection in adults who have not received prior antiretroviral therapy.
GSK and Verily to establish Galvani Bioelectronics – a new company dedicated to the development of bioelectronic medicines
GSK (LSE/NYSE: GSK) today announced an agreement with Verily Life Sciences LLC (formerly Google Life Sciences), an Alphabet company, to form Galvani Bioelectronics to enable the research, development and commercialisation of bioelectronic medicines. GSK will hold a 55% equity interest in the new jointly owned company and Verily will hold 45%.
Results announcement for the second quarter 2016 and half-yearly financial report for the half-year 2016
GSK delivers further progress against strategy with strong Q2 performance
Agreement further strengthens respiratory pipeline of targeted biological therapies
GSK today announced £275 million of new investments at three of its manufacturing sites in the UK to boost production and support delivery of its latest innovative respiratory and large molecule biological medicines. The vast majority of these products will be for export to global markets.
ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study which showed superior efficacy for Triumeq® (dolutegravir/abacavir/lamivudine) compared with atazanavir boosted with ritonavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in 495 treatment-naïve women living with HIV.
- Prize recognises innovations that are helping reduce child deaths
- This year’s Healthcare Innovation Award gives special attention to innovations which focus on the hardest-to-reach children
Since the outbreak of Zika virus disease began in the Americas late last year, GSK has been assessing how we can best help to respond. The World Health Organisation has declared Zika and the increase in neurological disorders and neonatal malformations associated with it to be a public health emergency of international concern.